Skip to main content

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

Active, not recruiting · Phase 3 · NCT03633799

Conditions: Women at Risk for Pregnancy

At a glance

Research payments reported, 2025
$1.2M
U.S. investigators named
38
Sites paid
60
Planned or actual enrollment
1,620

About the trial

Sponsor
Sebela Women's Health Inc. (with Syneos Health)
Tested
VeraCept (drug)
Dates
Started 2018-08-22; completion 2027-09-22
Results posted
Yes

To assess the contraceptive efficacy (prevention of pregnancy) of VeraCept

From ClinicalTrials.gov, last updated 2025-08-22. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sebela Women's Health Inc. reported $1.2M in research payments for this study in 2025 (473 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.